Astrazeneca Ab

Elizabeth Janet Pease

Robert Hugh Bradbury

Gloria Anne Breault

Emma Jane Williams

Jeffrey James Morris

Stuart Eric Pearson

Pyrimidine derivatives of formula (I) wherein: Qhand Qare independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one of Qand Qor both Qand Qis substituted on a ring carbon by one group selected from sulphamoyl, N&#x2014;(Calkyl)sulphamoyl (optionally substituted by halo or hydroxy), N,N-di-(Calkyl)sulphamoyl (optionally substituted by halo or hydroxy), Calkylsulphonyl (optionally substituted by halo or hydroxy) or a substituent of the formula (Ia) or (Ia'): wherein Q, Q, G, R, Y, Z, Q, n and m are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) inhibitors are also described 

Pyrimidine compounds

Pyrimidine derivatives of formula (I) wherein Q, Q, G and Rare as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.

2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents

2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents

Pyrimidine derivatives of the formula (I) wherein: one of Q and Q or both of Q and Q is substituted on a ring carbon by one substituent of the formula (Ia) &lsqb;provided that when present in Q the substituent of formula (Ia) is not adjacent to the &mdash;NH&mdash; link&rsqb;; wherein Q , Q , G, R , X, Y , Y , Z, n and m are as described within; and pharmaceutically acceptable salts and in vivo hydrolyzable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.

Pyrimidine derivatives of the formula (I), wherein: Q and Q are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one or both Q and Q are substituted on a ring carbon by one substituent of the formula (Ia) or (Ia&prime;), wherein: Y, Z, n, m Q , G, R , are as defined within; and pharmaceutically acceptable salts and in in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.

Growing community of inventors

Macclesfield, United Kingdom

Elizabeth Janet Pease